Therefore, TSA or 5-aza-dC can selectively upregulate IL-13Rα2 expression in breast cancer cells (particularly in non-TNBC), increasing their subsequent susceptibility to targeting via Pep-1-Phor21. The gene discussed is IL13RA2; the disease is breast carcinoma.